AJP - Renal AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Renal Physiol 290: F530-F541, 2006. First published September 20, 2005; doi:10.1152/ajprenal.00070.2005
0363-6127/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/2/F530    most recent
00070.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, W.
Right arrow Articles by Nielsen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, W.
Right arrow Articles by Nielsen, S.

Biphasic effects of ANP infusion in conscious, euvolumic rats: roles of AQP2 and ENaC trafficking

Weidong Wang,1 Chunling Li,1,2 Lene N. Nejsum,1 Hongyan Li,1 Soo Wan Kim,1 Tae-Hwan Kwon,3,1 Thomas E. N. Jonassen,4 Mark A. Knepper,5 Klaus Thomsen,6 Jørgen Frøkiær,1,2 and Søren Nielsen1

1The Water and Salt Research Center, University of Aarhus, and 2Institute of Clinical Medicine, Aarhus University Hospital-Skejby, Aarhus; 3Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Taegu, Korea; 4Department of Pharmacology, University of Copenhagen, Copenhagen; 5Laboratory of Kidney and Electrolyte Metabolism, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; and 6Institute for Basic Psychiatric Research, Department of Biological Psychiatry, Aarhus University Hospital, Aarhus, Denmark

Submitted 17 February 2005 ; accepted in final form 15 September 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Atrial natriuretic peptide (ANP) acutely promotes water and sodium excretion, whereas subchronic effects involve water retention. Renal hemodynamics, water and sodium excretion, and aquaporin-2 (AQP2) and epithelial Na channel (ENaC) subcellular trafficking were determined in response to continuous ANP infusion in conscious rats, where body sodium and fluid balance was constantly maintained. ANP (0.5 µg·kg–1·min–1) evoked a transient (peak at 10 min) fivefold diuresis followed by reduced urine production to control levels (30- to 90-min period). The fractional distal water excretion was significantly increased initially and then decreased in response to ANP. There was no change in the subcellular localization of AQP2 and AQP2 phosphorylated in PKA consensus site S256 (p-AQP2) 10 min after ANP infusion. In contrast, after 90 min a marked increase in apical labeling of AQP2 and p-AQP2 was observed in the inner and outer medullary collecting ducts but not in cortical collecting ducts. In support of this, ANP induced plasma membrane targeting of AQP2 in transiently AQP2-transfected cells. ANP infusion evoked an instant increase in renal sodium excretion, which persisted for 90 min. Ten minutes of ANP infusion induced no changes in the subcellular localization of ENaC subunits, whereas a marked increase in apical targeting of {alpha}- and {gamma}-subunits was observed after 90 min. In conclusion, 1) ANP infusion induced a sustained natriuresis and transient diuresis; 2) there were no changes in the subcellular localization of AQP2 and ENaC subunits after 10 min of ANP infusion; and 3) there was a marked increase in apical targeting of AQP2, p-AQP2, and {alpha}- and {gamma}-ENaC after 90 min of ANP infusion. The increased targeting of ENaC and AQP2 likely represents direct or compensatory effects to increase sodium and water reabsorption and to prevent volume depletion in response to prolonged ANP infusion.

aquaporin-2; atrial natriuretic peptide; cGMP; collecting duct; diuresis; epithelial sodium channel; natriuresis; servo-controlled replacement

ATRIAL NATRIURETIC PEPTIDE (ANP) is a potent natriuretic, diuretic, and vasodilatory peptide that contributes to blood pressure and volume homeostasis (13). ANP is released by cardiac myocytes in response to atrial distention in healthy subjects, and the plasma level of ANP has been found to be increased in patients with increased atrial pressure, including congestive heart failure and various disorders associated with expansion of extracellular fluid volume (reviewed in Ref. 6). ANP at various doses has been proven to have effects on systemic vasculature, cardiac effects, renal vasculature, renal water and electrolyte excretion, and changes in release of a number of different hormones (reviewed in Ref. 6).

The kidney is a major site of action by ANP. By concerted action both on renal vasculature and renal tubular epithelial cells, ANP demonstrates hemodynamic (6) and tubular effects that decrease tubular sodium and water reabsorption; the tubular effects probably predominate vs. the glomerular effects (2, 6, 7, 10). It is well established that ANP activates membrane-bound guanylyl cyclase and modulates cellular functions via the intracellular second messenger cGMP (reviewed in Ref. 6). Studies have provided evidence for stimulation of cGMP production in various renal tubule segments in response to ANP (26, 36) and for the expression of the cGMP-coupled ANP receptor (37) in these segments. ANP administration increases the plasma concentration and urinary excretion of cGMP (10, 18); however, the effect of ANP (through an increase in cGMP) on sodium and fluid transport in the collecting duct is still controversial. Some studies show that it decreases both sodium reabsorption and vasopressin-induced water transport in collecting ducts (14, 27, 28, 31), whereas others do not confirm these inhibitory effects (30, 32).

Moreover, several previous studies have shown that the diuresis and natriuresis induced by ANP are transient when given as continuous infusions or as repeated bolus injections (10, 15, 39) in humans and animals, because resistance to the diuretic and natriuretic actions of ANP develops after relatively brief periods of ANP infusion. A previous study demonstrated that a 4-h ANP infusion in conscious rats resulted in a significant diuresis and natriuresis during the first hour of infusion and then a decline of urine flow rate and urinary sodium excretion to the baseline level, whereas urinary cGMP excretion remained elevated for the duration of the ANP infusion (10). This suggested that either superimposed mechanisms (but not concomitant decline of cGMP) or direct effects of cGMP may blunt the diuretic and natriuretic effects of ANP. The resistance to the diuretic and natriuretic effects of ANP is also observed in pathophysiological states associated with edema formation, where increased release and elevated plasma level of ANP do not result in diuresis and natriuresis in the degree needed to obtain normal salt and water balance (1, 33). An understanding of the underlying mechanisms that resulted in the resistance to diuretic and natriuretic effects of ANP is becoming important in better understanding the long-term regulation of body water and sodium balance in both physiological and pathophysiological states.

The epithelial sodium channels (ENaC) and aquaporins (AQPs) have been demonstrated to play important roles in renal sodium and water reabsorption in the collecting duct. The apical plasma membrane expression of ENaC subunits ({alpha}, {beta}, and {gamma}) and AQP2 can be regulated by changes in the trafficking to the apical plasma membrane. In collecting duct principal cells, AQP2 is shuttled from intracellular vesicles to the apical plasma membrane on vasopressin stimulation; thus collecting duct water permeability, and hence water balance, is acutely regulated by vasopressin-regulated, cAMP-mediated trafficking of AQP2 (reviewed in Ref. 25). The hormone-regulated sodium reabsorption mediated by ENaC is associated with characteristic alterations in the subcellular localization of ENaC subunits (22, 23). Because the natriuretic peptide receptor is expressed in principal cells of the collecting duct (6), and changes in the subcellular localization of AQP2 also involve the activation of the cGMP-dependent pathway (4, 5), we hypothesized that the changes in the subcellular localization of ENaC subunits and AQP2 in the collecting duct principal cells could be involved in the transient phase of natriuresis and water diuresis induced by ANP infusion and in the following phase of decreased ANP effects on natriuresis and diuresis.

The purposes of this study were 1) to reexamine the effects of ANP on renal water and sodium regulation in conscious rats in which sodium and water balance was maintained by infusion of replacement sodium and fluid at a rate to match spontaneous urine losses (servo-controlled replacement) throughout the experiment; 2) to investigate the changes in the subcellular localization of renal collecting duct AQP2, phosphorylated-AQP2 (p-AQP2), and ENaC subunits in response to servo-controlled infusion of ANP at 10 and 90 min after initiation of infusion; and 3) to examine the intracellular AQP2 trafficking in transiently AQP2-transfected HEK 293 cells in response to direct ANP treatment in vitro (in a condition of the absence of vasopressin, angiotensin II, and aldosterone in the culture medium).


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. Specific pathogen-free female Wistar rats (190–220 g) were obtained from M&B (Ry, Denmark). The animals were housed in a temperature (22–24°C)- and humidity (60%)-controlled room with a 12:12-h light-dark cycle. The rats were fed a standard rodent diet (Altromin International, Lage, Germany) containing 120 mmol of sodium and 200 mmol of potassium/kg for at least 10 days before experimentation, with free access to water. For 3 days before the clearance study, lithium citrate was added to the food (15 mmol/kg) to obtain measurable plasma lithium concentration without influencing renal function. The animal protocols have been approved by the boards of the Institute of Anatomy and Institute of Clinical Medicine, University of Aarhus, according to the licenses for use of experimental animals issued by the Danish Ministry of Justice.

Surgical preparation. One week before experimentation, the animals were catheterized. The animals were anesthetized with Hypnorm (0.315 mg/ml fentanyl citrate+10 mg/ml fluanisone, 400 µl/kg, Janssen Pharmaceutica, Beerse, Belgium)-Dormicum (5 mg/ml midazolam, 800 µl/kg, Hoffmann-La Roche, Basel, Switzerland). With the use of aseptic surgical techniques, sterile Tygon catheters were advanced into the abdominal aorta and the inferior vena cava via the femoral vessels and exteriorized through an incision in the skin of the nape of the neck. A sterile chronic suprapubic bladder catheter was implanted and exteriorized through an incision in the abdominal wall. The arterial and venous catheters were sealed with a 50% glucose solution containing 500 U of heparin and 10,000 U of streptokinase/ml. After instrumentation, the rats were given 0.9% NaCl subcutaneously (sc; 5 ml) and a long-lasting analgesic (10 µg/animal sc, buprenorphinum, Temgesic, SheringPlough, Brussels, Belgium). They were housed individually and, after a recovery period of 5–6 days, they were acclimated to restraining cages to avoid stress during the investigation. The training consisted of three daily sessions with a stepwise increase in duration from 1 to 3 h.

Clearance protocol. The experiments were carried out between 9 AM and 2 PM, with the conscious rats immobilized in restraining cages. The rats were connected to a Baxter Uniflow blood pressure transducer via the arterial catheter. Through the pressure transducer, a continuous intra-arterial infusion of 25 mM glucose solution containing heparin (100 units/ml) was given at a rate of 5 µl/min to keep the arterial catheter open. Through the venous catheter, the animals received an infusion of 150 mM NaCl solution at a rate of 10 µl/min throughout the experiment (0.6-ml bolus sustained at 10 µl/min) containing [3H]inulin (1.8-µCi bolus, sustained at 0.03 µCi/min, Amersham International, Aylesbury, UK) and LiCl (7.2-µmol bolus sustained at 120 nmol/min). ANP (dissolved in demineralized water; A-8208, Sigma) was given at a dose of 0.5 µg·kg–1·min–1. Controls received vehicle alone. In addition, 25 mM glucose was given intravenously during the initial 120 min at a rate of 30 µl/min to provide an adequate minimum urine flow rate necessary for elimination of bladder-emptying errors. Furthermore, bladders were flushed with demineralized water at a rate of 100 µl/min. Blood samples of 250 µl were collected from the arterial catheter at –60, 0, 30, and 90 min after the start of ANP or vehicle infusion. All blood samples were replaced immediately with heparinized donor blood.

Servo-controlled system. During the final 90 min of the experiment where ANP was infused, the infusion of 25 mM glucose at a constant rate was stopped and the fluid-sodium balance was maintained by a computer-driven servo-controlled system. From the bladder catheter, urine passed a sodium-sensitive electrode, which performed one measurement of urinary sodium concentration per second (Nova Biochemical, Waltham, MA). Urine was collected every half hour in vials arranged in an autosampler placed on an electronic balance. The autosampler was operated by a photocell, which allowed one to change the vial without touching the balance. Data on urine production (weight on scale) and urinary sodium concentration were sampled continuously on an IBM-compatible computer, which, in turn, controlled the infusion rates of two independent infusion pumps (Harvard model 22, Scandidact, Kvistgaard, Denmark), which delivered 25 mM glucose and 1,200 mM NaCl, respectively. Urinary outputs of sodium and fluid were integrated over the course of 5 min, thus allowing a 5-min delay in changes of sodium and glucose infusion rates.

Analysis and calculations. Urine volume was determined gravimetrically. Plasma sodium, lithium, and urinary sodium concentrations were determined by flame emission photometry. [Li+] in the urine was determined by atomic absorption photometry. [3H]inulin activities in the plasma and urine were determined by liquid scintillation counting on a Packard Tri-Carb liquid scintillation analyzer (Packard Instruments, Meriden, CT). Plasma aldosterone concentrations were determined using a commercially available radioimmunoassay kit (Coat-A-Count, Diagnostic Products, Los Angeles, CA).

Renal clearances (C) and fractional excretions (FE) were calculated by the standard formulas as follows: C = U x V/P; FE = C/GFR, where U is urine concentration, V is the urine flow rate, P is the plasma concentration, and GFR is the glomerular filtration rate as measured by [3H]inulin clearance.

Cell culture. pCDNAI/Neo with rat cDNA encoding AQP2 (tagged with a COOH-terminal c-myc epitope) was generously provided by Dr. D. Brown (19). HEK 293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (vol/vol) fetal calf serum at 37°C in 5% CO2. HEK 293 cells were grown on coverslips coated with poly-D-lysine and transiently transfected using Effectene Transfection Reagent (Qiagen). Cells were kept in serum-free media with indomethacin (10 µM) overnight before the experiments and analyzed 48 h posttransfection. Cells were treated with forskolin (150 µM, Sigma) for 10 min or ANP (10 µM, Sigma) for 10 min. The experiment was repeated three times. Cells were fixed in 4% paraformaldehyde for 10 min, rinsed twice in PBS, and blocked for 15 min in blocking/permeabilization solution (PBS containing 0.1% BSA and 0.1% Triton X-100). Cells were incubated for 1 h at room temperature with primary antibody (see below) diluted in blocking solution, washed three times in PBS, and incubated with secondary antibody Alexa Fluor 488 goat anti-rabbit IgG (1:800, Molecular Probes) for 1 h at room temperature. After three final washes with PBS, the coverslips were mounted with glycagel (DAKO). Cells were analyzed using a Leica TCS-SP2 laser confocal microscope (Heidelberg, Germany).

Immunohistochemistry. Previously characterized rabbit polyclonal antibodies were used: AQP2(24), p-AQP2 (12), and {alpha}-, {beta}-, and {gamma}-ENaC subunits (17, 22, 23). For immunoperoxidase labeling, immediately after 10 or 90 min of ANP infusion, rat kidneys were fixed by retrograde perfusion via the aorta [2% paraformaldehyde, 0.1% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4)]. Kidney blocks containing all kidney zones were dehydrated and embedded in paraffin. The paraffin-embedded tissue was cut at 2 µm on a rotary microtome (Leica). The staining was carried out using indirect immunoperoxidase, as previously described (17). In brief, the sections were dewaxed and rehydrated. Endogenous peroxidase was blocked by 0.5% H2O2 in absolute methanol for 10 min at room temperature. Sections were incubated overnight at 4°C with primary antibodies diluted in PBS supplemented with 0.1% BSA and 0.3% Triton X-100. The sections were then washed with PBS followed by incubation in horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (DAKO P448) diluted in PBS supplemented with 0.1% BSA and 0.3% Triton X-100. The microscopic examination was carried out with a Leica DMRE light microscope (Leica Microsystems, Herlev, Denmark).

Data presentation and statistics. All values are presented as means ± SE. Individual comparisons within one group were performed by the use of Student's paired t-test, and individual comparisons between two groups were performed by an unpaired t-test. P values <0.05 were considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Rapid and transient increase in urine production in response to continuous ANP infusion. Urine production and sodium excretion were monitored in basal condition before ANP infusion (period 1: –60–0 min), in the first phase of ANP infusion (period 2: 0–30 min), and in the later phase of ANP infusion (period 3: 30–90 min, Fig. 1). Infusion of ANP (0.5 µg·kg–1·min–1) resulted in elevations in both urine flow rate and urinary sodium excretion rate (Fig. 1, A and B). During the baseline period (period 1), urine flow rate (V) and urinary sodium excretion rate were comparable between the two groups (Fig. 1, A and B). In contrast, ANP infusion induced a rapid increase in urine flow rate and peaked 10 min after the initiation of ANP infusion (Fig. 1A, period 2). Subsequently, the urinary flow rate returned to a level comparable to baseline (at 25 min) and maintained the basal level up to 90 min after onset of ANP infusion (Fig. 1A, period 3). Consistent with this, the fractional distal water excretion was significantly reduced (V/CLi, 9.1 ± 0.6 in period 2 vs. 3 ± 0.8% in period 3, P < 0.05, Table 1) in ANP-treated rats, suggesting that renal water reabsorption was increased in the collecting ducts in period 3 compared with period 2 despite continued infusion of ANP. In time-matched controls, the urine flow rate did not change during the whole experimental period (Fig. 1A).



View larger version (24K):
[in this window]
[in a new window]
  		Fig. 1. Time course of values for urinary flow rate (A) and urinary sodium excretion (B). {triangleup}, Control rats; {blacksquare}, atrial natriuretic peptide (ANP)-infused rats. ANP infusion starts in the treated animals at time 0. Period 1, –60–0 min; period 2, 0–30 min; period 3, 30–90 min. *P < 0.05 compared with control rats.

 

View this table:
[in this window]
[in a new window]
  		Table 1. Renal clearance data during periods 1, 2, and 3

 
Increased sodium excretion in response to ANP continuous infusion. The urinary sodium excretion rate increased significantly and peaked 15 min after the onset of ANP infusion and declined gradually after the peak but remained elevated compared with time-matched controls (Fig. 1B, periods 2 and 3). Thus in contrast to the effects of ANP on urine flow rate, the sodium excretion rate was maintained significantly higher throughout the 90-min infusion (Fig. 1B). Consistent with this, the fractional sodium excretion (FENa; 3.2 ± 0.3 vs. 0.4 ± 0.1%, Table 1) and fractional distal sodium excretion (CNa/CLi; 6.8 ± 1.1 vs. 1.1 ± 0.2%, Table 1) were significantly increased in period 2 compared with period 1. Similarly, significant differences were also observed in FENa (1.7 ± 0.6 vs. 0.4 ± 0.1%, Table 1) and CNa/CLi (4.1 ± 0.8 vs. 1.1 ± 0.2%, Table 1) in period 3 after ANP infusion compared with baseline period 1. Control rats did not show any changes in sodium excretion during the whole experiment (Table 1).

Absence of changes in proximal water/sodium reabsorption or in GFR in response to continuous ANP infusion. During periods 2 and 3, proximal tubular fluid output (Vprox, CLi) and fractional lithium excretion (FELi) did not change in any of the two groups (Table 1), indicating that ANP had little or no effect on proximal tubule water and sodium reabsorption. Similarly, GFR (CIn) did not change during ANP infusion (Table 1). In ANP-infused rats, mean arterial blood pressure (MAP) fell within 10 min following the start of ANP infusion and reached a stably low level throughout the infusion period. In control rats, MAP did not change throughout the whole experimental period. The difference in MAP between periods 1 and 3 was significant in ANP-infused rats (20 ± 3 vs. 6.8 ± 1 mmHg in control rats, P < 0.05, n = 6/group). Plasma electrolyte concentrations were similar before and during treatment with ANP (data not shown).

Absence of significant changes in apical labeling of AQP2 and p-AQP2 in IMCD principal cells in the initial phase of ANP infusion (period 2). Immunohistochemistry revealed no significant changes in the subcellular labeling of both AQP2 and p-AQP2 [using an antibody that selectively labels AQP2 phosphorylated in the PKA phosphorylation consensus site (Ser 256)] in the inner medullary collecting duct (IMCD) cells between controls and ANP-infused animals after 10 min of ANP infusion (Fig. 2, A–D).



View larger version (107K):
[in this window]
[in a new window]
  		Fig. 2. Immunoperoxidase microscopy of aquaporin-2 (AQP2) and AQP2 phosphorylated in PKA consensus site S256 (p-AQP2) in the inner medullary collecting duct (IMCD) in control rats (CON; A and C) and rats infused with ANP for 10 min (B and D). In both CON and ANP-treated rats, labeling for AQP2 (A and B) and p-AQP2 (C and D) is seen in both apical plasma membrane and intracellular domains in IMCD principal cells. There are no differences in subcellular distribution of AQP2 and p-AQP2 between the 2 groups. Magnification: x630.

 
Increased apical labeling of AQP2 and p-AQP2 in IMCD principal cells in response to 90 min of ANP infusion (period 3). We next tested the effect of ANP infusion on AQP2 and p-AQP2 expression in IMCD principal cells by immunohistochemistry in the late phase of ANP infusion (period 3). In control rats, immunoperoxidase microscopy revealed labeling of apical plasma membrane domains in all levels of the collecting duct. In the cortical collecting duct (CCD) and outer medullary collecting duct (OMCD), AQP2 was mainly associated with the apical plasma membrane and subapical domains (Fig. 3, A and C). In IMCD principal cells, AQP2 labeling was seen in both apical and basolateral plasma membrane domains as well as in intracellular domains (Fig. 3, E and G). In ANP-infused rats, AQP2 labeling in the CCD was mainly associated with the apical plasma membrane and subapical domains similar to the AQP2 labeling in control rats (Fig. 3B). In the inner stripe of outer medulla (ISOM), some principal cells exhibited increased apical labeling of AQP2 (arrow in Fig. 3D); however, most of the principal cells in the ISOM did not show different labeling distribution of AQP2 (not shown). In contrast, IMCD principal cells exhibited prominent apical labeling and notably substantially reduced basolateral and intracellular labeling (Fig. 3, F and H) of AQP2 in rats with ANP infusion compared with control rats. The increased apical trafficking of AQP2 is therefore consistent with the observed reduced urine flow rate in period 3. Similarly, there was a marked increase in the apical plasma membrane labeling of p-AQP2 in IMCD cells (arrow in Fig. 4D) compared with control rats (Fig. 4C). In contrast, no changes of p-AQP2 labeling were observed in cortical (Fig. 4B) and outer medullary collecting duct principal cells (not shown) in response to 90 min of ANP infusion.



View larger version (114K):
[in this window]
[in a new window]
  		Fig. 3. Immunoperoxidase microscopy of AQP2 in the cortical collecting duct (CCD), outer medullary collecting duct (OMCD), and IMCD from CON rats (A, C, E, and G) and rats infused with ANP for 90 min (B, D, F, and H). In the control rat, AQP2 is localized mainly in apical plasma membrane domains of CCD principal cells (A), whereas intercalated cells are not labeled (arrowhead). In OMCD principal cells, the immunolabeling of AQP2 is mainly associated with the apical plasma membrane and intracellular vesicles (C). In IMCD principal cells, AQP2 labeling is seen in both apical plasma membrane domains and intracellular domains (E and G). In the ANP-infused rats, similar labeling of AQP2 is seen in CCD principal cells (arrows in B), whereas some OMCD principal cells in the inner stripe of outer medulla show distinct apical labeling of AQP2 (arrow in D) with little intracellular labeling, whereas no intercalated cells are labeled (arrowhead in D). In contrast, IMCD principal cells exhibit prominent apical labeling of AQP2 and intracellular labeling of AQP2 is decreased (arrow in H). Magnification: x630 (A–D, G, and H); x250 (E and F).

 


View larger version (123K):
[in this window]
[in a new window]
  		Fig. 4. Immunoperoxidase microscopy of p-AQP2 in CCD and IMCD from CON rats (A and C) and rats infused with ANP 90 min (B and D). In the CON rats, p-AQP2 is localized mainly in apical plasma membrane domains of CCD principal cells (A), whereas intercalated cells were not labeled (arrowhead). In IMCD principal cells, p-AQP2 labeling is seen in both apical plasma membrane domains and intracellular domains (C). In the ANP-infused rats, similar labeling of p-AQP2 was seen in CCD principal cells (B), whereas IMCD principal cells exhibited prominent apical labeling and less intracellular labeling (arrow in D). Magnification: x630.

 
ANP stimulates AQP2 translocation in HEK 293 cells transiently transfected with AQP2. To confirm the in vivo results in a condition lacking vasopressin, angiotensin II, and aldosterone, all of which have been demonstrated to have effects on AQP2 regulation, we tested the direct effect of ANP treatment on the subcellular AQP2 localization in HEK 293 cells, which were transiently transfected with AQP2. In nontreated HEK 293 cells, AQP2 was exclusively localized in intracellular vesicles (arrowheads in Fig. 5A). In contrast, in response to forskolin, an activator of cAMP production, AQP2 was translocated to the plasma membrane (arrows in Fig. 5B). Stimulation with ANP also resulted in translocation of AQP2 to the plasma membrane (arrows in Fig. 5C), supporting the results obtained in vivo in the present study.



View larger version (49K):
[in this window]
[in a new window]
  		Fig. 5. Laser-scanning confocal immunofluorescence microscopy of AQP2 in HEK 293 cells transiently transfected with AQP2. In nonstimulated cells (control), AQP2 is mainly localized to intracellular vesicles (arrowheads in A). On stimulation with forskolin, AQP2 is translocated to the plasma membrane (arrows in B). Stimulation with ANP also induces translocation of AQP2 to the plasma membrane (arrows in C). Bar = 10 µm.

 
Increased apical labeling of {alpha}- and {gamma}-, but not {beta}-ENaC in CCD principal cells in response to prolonged ANP infusion. To investigate whether the intracellular trafficking of ENaC subunits is altered in ANP-infused rats, we carried out immunoperoxidase microscopy of {alpha}-, {beta}-, and {gamma}-subunits. Immunolabeling confirmed previous studies showing ENaC expression from the second half of the distal convoluted tubules (DCT2) to the IMCD, with the expression being most prominent in DCT2, connecting tubules (CNT), and CCD, with decreased labeling in medullary collecting duct segments (17). In control rats, immunoperoxidase microscopy demonstrated that immunolabeling of {alpha} (Fig. 6)-, {beta} (Fig. 7)-, and {gamma} (Fig. 8)-ENaC subunits was exclusively associated with the apical plasma membrane and the intracellular vesicles in DCT2, CNT, and CCD, consistent with previous findings (17) (data not shown for medullary collecting duct). After 10 min of ANP infusion, no significant changes were observed in the subcellular localization of ENaC subunits (not shown). In contrast, 90-min ANP infusion induced a marked increase in apical labeling of {alpha}-ENaC and {gamma}-ENaC in DCT2, CNT, and CCD principal cells (Fig. 6, B, D, and F, and Fig. 8, B, D, and F, respectively) compared with control rats (Fig. 6, A, C, and E, and Fig. 8, A, C, and E, respectively). No changes were observed in the IMCD (not shown). In contrast, the labeling of {beta}-ENaC was unchanged and showed both apical plasma membrane and dispersed cytoplasmic labeling in DCT2, CNT, CCD, and IMCD cells in both control (Fig. 7, A, C, and E) and ANP-infused rats (Fig. 7, B, D, and F). Therefore, the increased apical ENaC expression may suggest a possible compensation for the natriuresis induced by the continuous infusion of ANP. On the other hand, plasma aldosterone levels at period 3 did not show any significant difference between the two groups (1,608 ± 370 in ANP-infused rats vs. 1,565 ± 530 pg/ml in controls; not significant). These findings suggest that plasma aldosterone may not play a role in the increased apical targeting of ENaC subunits in rats with ANP infusion.



View larger version (165K):
[in this window]
[in a new window]
  		Fig. 6. Immunoperoxidase microscopy of the {alpha}-subunit of the epithelial sodium channel ({alpha}-ENaC) in the second half of the distal convoluted tubule (DCT2), connecting tubule (CNT), and CCD from CON rats (A, C, and E) and rats infused with ANP for 90 min (B, D, and F). Immunoperoxidase labeling of {alpha}-ENaC is dispersed in the cytoplasm of the principal cells in the DCT2 (A), CNT (C), and CCD (E) from CON rats, whereas ANP-infused rats showed distinct apical immunolabeling of {alpha}-ENaC in the DCT2 (B), CNT (D), and CCD (F). Arrows indicate apical labeling of {alpha}-ENaC, whereas arrowheads indicate intercalated cells. Magnification: x1,000.

 


View larger version (164K):
[in this window]
[in a new window]
  		Fig. 7. Immunoperoxidase microscopy of {beta}-ENaC in DCT2, CNT, and CCD from CON rats (A, C, and E) and rats infused with ANP for 90 min (B, D, and F). Immunoperoxidase labeling of {beta}-ENaC is mainly associated with intracellular vesicles dispersed in the entire cytoplasm of principal cells of the DCT2 (A), CNT (C), and CCD (E) in CON rats. Similarly, immunoperoxidase staining for {beta}-ENaC revealed diffuse cytoplasmic labeling throughout the DCT2 (B), CNT (D), and CCD (F) in ANP-infused rats, indicating unchanged subcellular localization. Arrowheads indicate intercalated cells. Magnification: x1,000.

 


View larger version (165K):
[in this window]
[in a new window]
  		Fig. 8. Immunoperoxidase microscopy of {gamma}-ENaC in DCT2, CNT, and CCD from CON rats (A, C, and E) and rats infused with ANP for 90 min (B, D, and F). Immunoperoxidase labeling of {gamma}-ENaC is mainly observed to be dispersed in the cytoplasm of principal cells in the DCT2 (A), CNT (C), and CCD (E) in CON rats. In contrast, {gamma}-ENaC labeling is predominantly localized to the apical plasma membrane domains in DCT2 (B), CNT (D), and CCD (F) principal cells of ANP-infused rats. Arrows indicate apical labeling of {gamma}-ENaC, whereas arrowheads indicate intercalated cells. Magnification: x1,000.

 
Absence of significant changes in labeling of NHE3, NKCC2, and Na-K-ATPase in thick ascending limbs in the initial phase of ANP infusion. As we described, proximal tubular fluid output and FELi did not change in response to ANP treatment during period 2 despite increased urinary sodium and water excretion. Moreover, in period 2 no significant changes were observed in the subcellular localization of ENaC subunits in the collecting ducts after 10 min of ANP infusion. We next examined whether there were alterations in the subcellular localization or overall labeling of thick ascending limb sodium transporters (Na-K-2Cl cotransporter: NKCC2, Na/H exchanger type 3: NHE3, Na-K-ATPase {alpha}1-subunit) to study whether the initial natriuretic effect after ANP treatment was associated with decreased targeting of these proteins in thick ascending limb cells. As shown in Fig. 9, immunoperoxidase microscopy revealed that the overall labeling and the subcellular localization of these transport proteins were unchanged compared with controls (Fig. 9, A–F).



View larger version (143K):
[in this window]
[in a new window]
  		Fig. 9. Immunoperoxidase microscopy of Na-K-ATPase, Na/H exchanger type 3 (NHE3), and Na-K-2Cl cotransporter type 1 (NKCC2) in the outer medullary thick ascending limbs (mTAL) from CON rats (A, C, and E) and rats infused with ANP for 10 min (B, D, and F). In both CON and ANP-treated rats, NHE3 and NKCC2 immunolabeling was present in the apical plasma membrane domains, whereas Na-K-ATPase labeling was seen associated with the basolateral plasma membrane in the mTAL cells. There are no obvious differences in the subcellular distribution of these 3 proteins between the 2 groups. Magnification: x630.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The present study was performed to examine the effects of ANP on renal sodium and water metabolism and on the regulation of intracellular AQP2 and ENaC trafficking. The overall purpose was to examine whether changes in subcellular localization of AQP2 and ENaC subunits could explain the marked changes in the water and sodium metabolism seen in response to acute (10 min) and subacute (90 min) ANP treatment, with the initial phase promoting diuresis and the later phase revealing a resistance to diuretic effect of ANP. ANP infusion results in a rapid, transient diuresis and a persistent increase in urinary sodium excretion with no changes in GFR and no changes in the subcellular localization of AQP2 and ENaC subunits in the initial phase. This indicates that changes in AQP2 and ENaC subunits do not play a major role in ANP-induced diuresis and natriuresis in the initial phase. In contrast, ANP infusion for 90 min was associated with an increased translocation of AQP2 and ENaC to the apical plasma membrane in the principal cells of collecting ducts, suggesting a compensatory process in response to persistently increased urinary sodium excretion induced by ANP.

Anesthesia and changes in body fluid homeostasis are known to influence the circulating concentrations of hormones, including vasopressin and ANP (7, 40). To exclude the confounding influence of anesthesia and disturbances in body fluid status, which are often seen in experimental animals on fixed-infusion regimens, the present experiments were conducted in chronically catheterized, conscious rats using the servo-controlled, fluid-balanced, fluid-replacement technique to maintain the extracellular fluid volume in these animals.

ANP-induced diuresis and natriuresis and its resistance. In the present study, continuous ANP infusion induced diuresis and natriuresis, consistent with previous studies in animals and humans (2, 7, 8, 10, 39). The effect of ANP (lowering of blood pressure) was persistent throughout the study. In contrast, GFR was slightly, but insignificantly increased during periods when diuresis and natriuresis were highest (period 2), although a transient change in GFR at a certain time point cannot be excluded. Unchanged GFR in response to ANP infusion was consistent with previous studies in which the dosages of ANP were one-half or two-thirds that of the dose used in this study (2, 7, 10). It is likely that systemic ANP infusion does not alter the GFR level despite a significant decrease in systemic blood pressure. The fact that urinary sodium excretion was elevated despite a fall in blood pressure supports the idea that ANP acts on the kidney to shift the so-called pressure-natriuresis curve. Persistent reduction of MAP was also seen in the other servo-controlled study (2). Mechanisms by which ANP reduce blood pressure include diminished cardiac output, reductions in peripheral vascular resistance, vasodilation, and decreased intravascular volume, volume status, and circulating hormone (6). Maintenance of extracellular fluid by a servo-controlled system may not fully prevent the hypotensive effect of ANP.

The observed occurrence of diuresis and natriuresis without a detectable change in GFR in response to ANP infusion would be compatible with the hypothesis that ANP also directly alters renal tubule sodium and water reabsorption. In the present study, the proximal tubular fluid output (CLi) and FELi were not changed by the infusion of ANP, indicating that ANP-induced natriuresis is associated with the decreased sodium reabsorption in the distal nephron and collecting duct, but not in the proximal tubule. The loss of water and sodium after ANP infusion was immediately replaced by the servo-controlled system, and this gave us the opportunity to examine the effect of ANP on sodium and water excretion when the renal effect of ANP was unopposed by sodium and water losses. Surprisingly, after an initial peak in urine flow rate, it went down to the baseline level. In contrast, sodium excretion, after an initial peak, remained elevated by fivefold compared with the pretreatment baseline level. In our studies, resistance or blunted effects to the diuresis and natriuresis developed after 30 min of ANP infusion. These are consistent with previous observations (10, 15, 16). However, immunohistochemistry revealed unchanged targeting of the sodium transporters in the thick ascending limb as well as ENaC subunits in the collecting duct, despite natriuresis and diuresis in this period. Thus the molecular basis for this ANP resistance remains largely undefined.

ANP treatment increased membrane targeting of AQP2 and p-AQP2 in the IMCD cells in vivo and HEK 293 cells in vitro. Our results showed that the later phase, showing resistance to the diuretic effect of ANP, was associated with enhanced apical labeling of AQP2 and p-AQP2 in IMCD principal cells. This finding was confirmed by our in vitro studies, which showed that ANP induced plasma membrane insertion of AQP2 in HEK 293 cells transiently transfected with AQP2. Together with a previous study demonstrating cGMP-dependent membrane insertion of AQP2 in renal epithelial cells (4, 5), the present data further suggest a cGMP-dependent pathway for AQP2 membrane insertion in renal epithelial cells, in addition to a cAMP-dependent pathway.

AQP2 is the primary target for vasopressin regulation of collecting duct water permeability and body water balance. The most widely understood pathway leading to AQP2 membrane targeting is via vasopressin V2 receptor-mediated stimulation of adenylyl cyclase, cAMP-mediated activation of protein kinase A, and phosphorylation of AQP2. AQP2 is then translocated from intracellular vesicles to the plasma membrane, thereby increasing the water permeability of the apical plasma membrane (reviewed in Ref. 25). These studies emphasized the important roles of cAMP in mediating AQP2 trafficking under vasopressin regulation. In addition, recent studies demonstrated a cAMP-independent and cGMP-dependent pathway for AQP2 membrane insertion in renal epithelial cells (4, 5). In these studies, exogenous cGMP or increased endogenous cGMP levels induced by sodium nitroprusside and ANP treatment stimulated relocation of AQP2 from cytoplasmic vesicles to the plasma membrane in rat kidney collecting duct principal cells and LLC-PK1 cells stably transfected with AQP2 (4). The observed AQP2 membrane insertion by elevated intracellular cGMP could be achieved by inhibition of cGMP phosphodiesterases (5). Consistent with these findings, the present data showed a strong plasma membrane staining for AQP2 in HEK cells transfected with AQP2 exposed to ANP. Moreover, importantly, we demonstrate a strong apical plasma membrane labeling of AQP2 and p-AQP2 in IMCD principal cells of rats infused with ANP. It should be noted that it is unclear whether the AQP2 trafficking is a direct effect of cGMP and ANP or a secondary effect.

The selective effect of ANP to induce AQP2 plasma trafficking changes in IMCD remains unclear. However, this is consistent with recent evidence of a cGMP-mediated (by ANP and inhibition of cGMP phosphodiesterases) increase in AQP2 accumulation in the apical plasma membrane of principal cells mainly in the medullary collecting ducts (4, 5), suggesting that medullary collecting duct principal cells appears to be more sensitive to ANP (or cGMP) than CCD for AQP2 translocation. Further studies are needed to clarify the detailed cellular mechanisms of ANP-induced AQP2 regulation.

ANP induced translocation of {alpha}- and {gamma}-ENaC subunits to the plasma membrane. Consistent with previous studies, ANP infusion led to an acute increase in sodium excretion. The greatest natriuretic effect was seen 15 min after infusion, and then the urinary sodium excretion went down to a plateau that was about five times higher than the baseline level. FENa and CNa/CLi at the plateau were also lower than the levels observed at the peak, suggesting the existence of a compensatory effect in the distal nephron and the collecting duct. The changes in urinary sodium excretion were associated with increased apical labeling of {alpha}- and {gamma}-ENaC subunits in the DCT2, CNT, and CCD. Thus it is believed that the reabsorption of sodium through the apical membrane by {alpha}- and {gamma}-ENaC in these renal tubular segments compensates for increased sodium excretion during the peak time.

The apical plasma membrane expression of ENaC can be altered by changes in the trafficking of the channel subunits to the apical plasma membrane under hormone regulation. These studies suggested that translocation of ENaC to the apical plasma membrane is strictly regulated by several hormones, such as aldosterone (22, 23), vasopressin (20), and angiotensin II (3). However, the regulatory mechanisms involved in the altered apical plasma membrane expression of ENaC seen in response to ANP are not clear. It may represent direct effects of ANP or potentially also involve secondary effects by other hormonal systems. Two previous studies using similar techniques have shown unchanged plasma vasopressin levels during ANP infusion (2, 7). Thus it appears unlikely that AVP is involved in the translocation of ENaC subunits to the apical plasma membrane. ANP is known to directly inhibit adrenal aldosterone (11) and renin (9) secretion and to be indirectly involved in the regulation of sodium reabsorption through suppressing the renin-angiotensin-aldosterone axis. In the two studies on euvolemic rats infused with ANP, aldosterone levels were reduced in one study (7), but maintained in the other (2). Aldosterone levels did not change in response to ANP infusion in the present study, indicating other factors rather than hormones may regulate apical expression of ENaC subunits. Whether intrarenal angiotensin II levels may be increased in ANP-infused rats cannot be ascertained from the present data.

In the present study, ANP infusion induced significant natriuresis. However, apical targeting of ENaC subunits was markedly increased, which plays a role in sodium reabsorption in the distal nephron and collecting duct. Thus a straightforward interpretation of these results would be that lack of downregulation of ENaC expression at the site of function, the apical plasma membrane, in the distal nephron speaks against changes in ENaC subunits playing a role in ANP-induced natriuresis and diuresis. Besides ENaC, an amiloride-sensitive, cGMP-gated cation channel located in the apical membrane of kidney cells is revealed to mediate transepithelial sodium reabsorption across the distal nephron and the collecting ducts (21). Because the rates of electrogenic, amiloride-sensitive sodium absorption in the CCD and IMCD are similar (29, 34, 38), the observation that ENaC expression is lower in IMCD than in CCD suggests that another channel, such as the cGMP-gated cation channel, along with ENaC participates in electrogenic sodium absorption across the IMCD. ANP (via cGMP) has been demonstrated to reduce electrogenic sodium absorption across the IMCD by inhibiting the cGMP-gated cation channel (21, 35). By functioning independently and/or by being regulated independently, two sodium-conducting channels may impart more diverse and precise control over sodium reabsorption, which is essential for the regulation and maintenance of extracellular fluid volume.

The present study raised a possible explanation for the resistance to diuresis and natriuresis of ANP during prolonged ANP infusion seen in other studies (10, 39) and some chronic edematous states in which positive sodium balance persists despite elevated plasma levels of ANP (1, 33). In these studies, prolonged ANP infusion induced a transient diuresis and natriuresis despite persistently increased urinary cGMP excretion in rats. In patients with heart failure, ANP levels are elevated and a linear relationship between plasma ANP and urinary cGMP is observed (1). These data indicated a potential role of cGMP in mediating ANP's effects. ANP-induced, cGMP-mediated apical plasma membrane expression of AQP2, p-AQP2, and {alpha}- and {gamma}-ENaC may promote water and sodium reabsorption in the distal nephron and the collecting ducts and may be involved, at least in part, in the evanescence of diuresis/natriuresis and water and sodium retention in some conditions. However, further studies are warranted to examine the mechanisms for the development of ANP resistance.

In summary, our study demonstrated that continuous infusion of ANP evoked a transient, significant diuresis and sustained natriuresis in conscious, euvolemic rats. ANP administration was associated with strong apical plasma membrane labeling of AQP2 and p-AQP2 in the IMCD principal cells and plasma membrane insertion of AQP2 in HEK cells transiently transfected with AQP2. It is likely that ANP via cGMP induces an intracellular redistribution of AQP2. Prolonged ANP stimulation was also associated with enhanced apical plasma membrane location of {alpha}- and {gamma}- but not {beta}-ENaC in the CCD, potentially indicating a local regulation of ENaC translocation in the kidney in response to increased urinary sodium excretion induced by ANP.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
Support for this study was provided by the Karen Elise Jensen Foundation, Human Frontier Science Program, Novo Nordic Foundation, Danish Medical Research Council, University of Aarhus Research Foundation, the University of Aarhus, the European Commission (QRLT 2000 00778 and QRLT 2000 00987), the Regional Technology Innovation Program of the MOCIE (RTI04–01-01, T.-H. Kwon), and the intramural budget of the National Heart, Lung, and Blood Institute.


   ACKNOWLEDGMENTS
 
The authors thank Jette Birk, Inger Merete Paulsen, Gitte Kall, Ida Maria Jalk, Merete Pedersen, Mette Vistisen, Zhila Nikrozi, Helle Høyer, Lotte Vallentin Holbech, and Dorte Wulff for expert technical assistance. The Water and Salt Research Center at the University of Aarhus is established and supported by the Danish National Research Foundation (Danmarks Grundforskningsfond).


   FOOTNOTES
 

Address for reprint requests and other correspondence: S. Nielsen, The Water and Salt Research Ctr., Institute of Anatomy, Univ. of Aarhus, DK-8000 Aarhus C, Denmark (e-mail: sn{at}ana.au.dk)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abraham WT, Hensen J, Kim JK, Durr J, Lesnefsky EJ, Groves BM, and Schrier RW. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. J Am Soc Nephrol 2: 1697–1703, 1992.[Abstract]
  2. Abu-Amarah I and Balment RJ. Vascular, renal, and endocrine responses to low-dose atrial natriuretic peptide in the fluid-balanced New Zealand genetically hypertensive rats with and without endogenous arginine vasopressin. Can J Physiol Pharmacol 77: 102–110, 1999.[CrossRef][Web of Science][Medline]
  3. Beutler KT, Masilamani S, Turban S, Nielsen J, Brooks HL, Ageloff S, Fenton RA, Packer RK, and Knepper MA. Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension 41: 1143–1150, 2003.[Abstract/Free Full Text]
  4. Bouley R, Breton S, Sun T, McLaughlin M, Nsumu NN, Lin HY, Ausiello DA, and Brown D. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest 106: 1115–1126, 2000.[Web of Science][Medline]
  5. Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, and Brown D. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am J Physiol Renal Physiol 288: F1103–F1112, 2005.[Abstract/Free Full Text]
  6. Brenner BM, Ballermann BJ, Gunning ME, and Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 70: 665–699, 1990.[Free Full Text]
  7. Burgess WJ and Balment RJ. The involvement of vasopressin in the renal actions of atrial natriuretic peptide in conscious fluid-balanced rats. J Endocrinol 138: 413–420, 1993.[Abstract/Free Full Text]
  8. Burgess WJ and Balment RJ. Plasma atrial natriuretic peptide in vasopressin deficiency: the effects of acute water deprivation in rats. J Endocrinol 135: 431–438, 1992.[Abstract/Free Full Text]
  9. Burnett JC Jr, Granger JP, and Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol Renal Fluid Electrolyte Physiol 247: F863–F866, 1984.[Abstract/Free Full Text]
  10. Campbell HT, Lightfoot BO, and Sklar AH. Four-hour atrial natriuretic peptide infusion in conscious rats: effects on urinary volume, sodium, and cyclic GMP. Proc Soc Exp Biol Med 189: 317–324, 1988.[CrossRef][Medline]
  11. Chartier L, Schiffrin E, Thibault G, and Garcia R. Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin II, ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo. Endocrinology 115: 2026–2028, 1984.[Abstract/Free Full Text]
  12. Christensen BM, Zelenina M, Aperia A, and Nielsen S. Localization and regulation of PKA-phosphorylated AQP2 in response to V2-receptor agonist/antagonist treatment. Am J Physiol Renal Physiol 278: F29–F42, 2000.[Abstract/Free Full Text]
  13. De Bold AJ, Borenstein HB, Veress AT, and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28: 89–94, 1981.[CrossRef][Web of Science][Medline]
  14. Dillingham MA and Anderson RJ. Inhibition of vasopressin action by atrial natriuretic factor. Science 231: 1572–1573, 1986.[Abstract/Free Full Text]
  15. Garcia R, Cantin M, Genest J, Gutkowska J, and Thibault G. Body fluids and plasma atrial peptide after its chronic infusion in hypertensive rats. Proc Soc Exp Biol Med 185: 352–358, 1987.[Medline]
  16. Granger JP, Opgenorth TJ, Salazar J, Romero JC, and Burnett JC Jr. Long-term hypotensive and renal effects of atrial natriuretic peptide. Hypertension 8: II112-II116, 1986.[Medline]
  17. Hager H, Kwon TH, Vinnikova AK, Masilamani S, Brooks HL, Frøkiær J, Knepper MA, and Nielsen S. Immunocytochemical and immunoelectron microscopic localization of {alpha}-, {beta}-, and {gamma}-ENaC in rat kidney. Am J Physiol Renal Physiol 280: F1093–F1106, 2001.[Abstract/Free Full Text]
  18. Huang CL, Ives HE, and Cogan MG. In vivo evidence that cGMP is the second messenger for atrial natriuretic factor. Proc Natl Acad Sci USA 83: 8015–8018, 1986.[Abstract/Free Full Text]
  19. Katsura T, Verbavatz JM, Farinas J, Ma T, Ausiello DA, Verkman AS, and Brown D. Constitutive and regulated membrane expression of aquaporin 1 and aquaporin 2 water channels in stably transfected LLC-PK1 epithelial cells. Proc Natl Acad Sci USA 92: 7212–7216, 1995.[Abstract/Free Full Text]
  20. Kleyman TR, Ernst SA, and Coupaye-Gerard B. Arginine vasopressin and forskolin regulate apical cell surface expression of epithelial Na+ channels in A6 cells. Am J Physiol Renal Fluid Electrolyte Physiol 266: F506–F511, 1994.[Abstract/Free Full Text]
  21. Light DB, Schwiebert EM, Karlson KH, and Stanton BA. Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. Science 243: 383–385, 1989.[Abstract/Free Full Text]
  22. Loffing J, Zecevic M, Feraille E, Kaissling B, Asher C, Rossier BC, Firestone GL, Pearce D, and Verrey F. Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. Am J Physiol Renal Physiol 280: F675–F682, 2001.[Abstract/Free Full Text]
  23. Masilamani S, Kim GH, Mitchell C, Wade JB, and Knepper MA. Aldosterone-mediated regulation of ENaC {alpha}, {beta}, and {gamma} subunit proteins in rat kidney. J Clin Invest 104: R19–R23, 1999.[Medline]
  24. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, and Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 92: 1013–1017, 1995.[Abstract/Free Full Text]
  25. Nielsen S, Frøkiær J, Marples D, Kwon TH, Agre P, and Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205–244, 2002.[Abstract/Free Full Text]
  26. Nonoguchi H, Knepper MA, and Manganiello VC. Effects of atrial natriuretic factor on cyclic guanosine monophosphate and cyclic adenosine monophosphate accumulation in microdissected nephron segments from rats. J Clin Invest 79: 500–507, 1987.[Web of Science][Medline]
  27. Nonoguchi H, Sands JM, and Knepper MA. Atrial natriuretic factor inhibits vasopressin-stimulated osmotic water permeability in rat inner medullary collecting duct. J Clin Invest 82: 1383–1390, 1988.[Web of Science][Medline]
  28. Nonoguchi H, Sands JM, and Knepper MA. ANF inhibits NaCl and fluid absorption in cortical collecting duct of rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 256: F179–F186, 1989.[Abstract/Free Full Text]
  29. Reif MC, Troutman SL, and Schafer JA. Sodium transport by rat cortical collecting tubule. Effects of vasopressin and desoxycorticosterone. J Clin Invest 77: 1291–1298, 1986.[Web of Science][Medline]
  30. Rouch AJ, Chen L, Troutman SL, and Schafer JA. Na+ transport in isolated rat CCD: effects of bradykinin, ANP, clonidine, and hydrochlorothiazide. Am J Physiol Renal Fluid Electrolyte Physiol 260: F86–F95, 1991.[Abstract/Free Full Text]
  31. Sands JM, Nonoguchi H, and Knepper MA. Hormone effects on NaCl permeability of rat inner medullary collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 255: F421–F428, 1988.[Abstract/Free Full Text]
  32. Schlatter E, Cermak R, Forssmann WG, Hirsch JR, Kleta R, Kuhn M, Sun D, and Schafer JA. cGMP-activating peptides do not regulate electrogenic electrolyte transport in principal cells of rat CCD. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1158–F1165, 1996.[Abstract/Free Full Text]
  33. Shenker Y, Sider RS, Ostafin EA, and Grekin RJ. Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest 76: 1684–1687, 1985.[Web of Science][Medline]
  34. Stanton BA. Characterization of apical and basolateral membrane conductances of rat inner medullary collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 256: F862–F868, 1989.[Abstract/Free Full Text]
  35. Stanton BA. Molecular mechanisms of ANP inhibition of renal sodium transport. Can J Physiol Pharmacol 69: 1546–1552, 1991.[Web of Science][Medline]
  36. Takeda S, Kusano E, Murayama N, Asano Y, Hosoda S, Sokabe H, and Kawashima H. Atrial natriuretic peptide elevates cGMP contents in glomeruli and in distal tubules of rat kidney. Biochem Biophys Res Commun 136: 947–954, 1986.[CrossRef][Web of Science][Medline]
  37. Terada Y, Moriyama T, Martin BM, Knepper MA, and Garcia-Perez A. RT-PCR microlocalization of mRNA for guanylyl cyclase-coupled ANF receptor in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 261: F1080–F1087, 1991.[Abstract/Free Full Text]
  38. Tomita K, Pisano JJ, and Knepper MA. Control of sodium and potassium transport in the cortical collecting duct of the rat. Effects of bradykinin, vasopressin, and deoxycorticosterone. J Clin Invest 76: 132–136, 1985.[Web of Science][Medline]
  39. Waldhausl W, Vierhapper H, and Nowotny P. Prolonged administration of human atrial natriuretic peptide in healthy men: evanescent effects on diuresis and natriuresis. J Clin Endocrinol Metab 62: 956–959, 1986.[Abstract/Free Full Text]
  40. Walker LA, Buscemi-Bergin M, and Gellai M. Renal hemodynamics in conscious rats: effects of anesthesia, surgery, and recovery. Am J Physiol Renal Fluid Electrolyte Physiol 245: F67–F74, 1983.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Klokkers, P. Langehanenberg, B. Kemper, S. Kosmeier, G. von Bally, C. Riethmuller, F. Wunder, A. Sindic, H. Pavenstadt, E. Schlatter, et al.
Atrial natriuretic peptide and nitric oxide signaling antagonizes vasopressin-mediated water permeability in inner medullary collecting duct cells
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F693 - F703.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Boone, M. Kortenoeven, J. H. Robben, and P. M. T. Deen
Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus
Nephrol. Dial. Transplant., August 8, 2009; (2009) gfp409v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. H. Robben, N. V. A. M. Knoers, and P. M. T. Deen
Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus.
Am J Physiol Renal Physiol, August 1, 2006; 291(2): F257 - F270.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/2/F530    most recent
00070.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, W.
Right arrow Articles by Nielsen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, W.
Right arrow Articles by Nielsen, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.